Targeted Biologics Show Promise for Severe Allergy in Rare Genetic Immune Disorders
A new systematic review of 172 patients finds that dupilumab, omalizumab, and JAK inhibitors can meaningfully control severe atopic disease ...
A new systematic review of 172 patients finds that dupilumab, omalizumab, and JAK inhibitors can meaningfully control severe atopic disease ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine